[go: up one dir, main page]

LT3484888T - Kietosios ttk inhibitoriaus formos - Google Patents

Kietosios ttk inhibitoriaus formos

Info

Publication number
LT3484888T
LT3484888T LTEPPCT/CA2017/050848T LTCA2017050848T LT3484888T LT 3484888 T LT3484888 T LT 3484888T LT CA2017050848 T LTCA2017050848 T LT CA2017050848T LT 3484888 T LT3484888 T LT 3484888T
Authority
LT
Lithuania
Prior art keywords
solid forms
ttk inhibitor
ttk
inhibitor
solid
Prior art date
Application number
LTEPPCT/CA2017/050848T
Other languages
English (en)
Inventor
Sze-Wan Li
Heinz W. Pauls
Peter Brent Sampson
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of LT3484888T publication Critical patent/LT3484888T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Metallurgy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/CA2017/050848T 2016-07-18 2017-07-13 Kietosios ttk inhibitoriaus formos LT3484888T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (1)

Publication Number Publication Date
LT3484888T true LT3484888T (lt) 2023-06-12

Family

ID=60991755

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CA2017/050848T LT3484888T (lt) 2016-07-18 2017-07-13 Kietosios ttk inhibitoriaus formos

Country Status (26)

Country Link
US (3) US10584130B2 (lt)
EP (1) EP3484888B1 (lt)
JP (2) JP6961675B2 (lt)
KR (2) KR102700233B1 (lt)
CN (2) CN109476667B (lt)
AU (2) AU2017299850B2 (lt)
BR (1) BR112019000813A2 (lt)
CA (1) CA3030230A1 (lt)
DK (1) DK3484888T3 (lt)
ES (1) ES2945108T3 (lt)
FI (1) FI3484888T5 (lt)
HR (1) HRP20230481T1 (lt)
HU (1) HUE061872T2 (lt)
IL (1) IL264173B2 (lt)
LT (1) LT3484888T (lt)
MA (1) MA45691A (lt)
MX (2) MX385289B (lt)
PL (1) PL3484888T3 (lt)
PT (1) PT3484888T (lt)
RS (1) RS64210B1 (lt)
RU (2) RU2021124795A (lt)
SG (2) SG10202103332UA (lt)
SI (1) SI3484888T1 (lt)
SM (1) SMT202300156T1 (lt)
TW (2) TWI745400B (lt)
WO (1) WO2018014116A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45691A (fr) 2016-07-18 2019-05-22 Univ Health Network Formes solides d'inhibiteur de ttk
KR20240175121A (ko) 2023-06-12 2024-12-19 한국재료연구원 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377596B1 (en) 2001-02-21 2012-04-11 Novartis Vaccines and Diagnostics, Inc. Ttk in diagnosis and as a therapeutic target in cancer
MX337817B (es) * 2004-11-04 2011-11-04 Vertex Pharma Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
NZ707432A (en) 2012-11-16 2020-01-31 Univ Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
MA45691A (fr) 2016-07-18 2019-05-22 Univ Health Network Formes solides d'inhibiteur de ttk

Also Published As

Publication number Publication date
JP2022001598A (ja) 2022-01-06
CN115093416A (zh) 2022-09-23
RS64210B1 (sr) 2023-06-30
US11104681B2 (en) 2021-08-31
HUE061872T2 (hu) 2023-08-28
US20200270259A1 (en) 2020-08-27
CN115093416B (zh) 2024-04-12
MX385289B (es) 2025-03-18
HRP20230481T1 (hr) 2023-07-21
WO2018014116A1 (en) 2018-01-25
AU2017299850B2 (en) 2021-05-27
TWI824313B (zh) 2023-12-01
CA3030230A1 (en) 2018-01-25
US10584130B2 (en) 2020-03-10
EP3484888B1 (en) 2023-02-22
KR20190029601A (ko) 2019-03-20
FI3484888T5 (fi) 2024-02-26
IL264173A (en) 2019-02-28
KR102700233B1 (ko) 2024-08-28
EP3484888A1 (en) 2019-05-22
US20220089601A1 (en) 2022-03-24
RU2019101109A3 (lt) 2021-02-05
NZ749844A (en) 2024-03-22
IL264173B1 (en) 2025-01-01
FI3484888T3 (fi) 2023-05-03
ES2945108T3 (es) 2023-06-28
JP7263473B2 (ja) 2023-04-24
BR112019000813A2 (pt) 2019-04-30
RU2019101109A (ru) 2020-08-18
CN109476667B (zh) 2022-06-28
MX2019000744A (es) 2019-05-02
PL3484888T3 (pl) 2023-06-26
JP2019521155A (ja) 2019-07-25
EP3484888A4 (en) 2020-01-08
AU2021221447A1 (en) 2021-10-07
RU2021124795A (ru) 2021-09-14
DK3484888T3 (da) 2023-05-30
SG10202103332UA (en) 2021-05-28
AU2017299850A8 (en) 2019-03-21
SMT202300156T1 (it) 2023-07-20
PT3484888T (pt) 2023-05-26
RU2753905C2 (ru) 2021-08-24
US20190292193A1 (en) 2019-09-26
US11878980B2 (en) 2024-01-23
MA45691A (fr) 2019-05-22
AU2017299850A1 (en) 2019-01-24
SI3484888T1 (sl) 2023-07-31
TW201803876A (zh) 2018-02-01
IL264173B2 (en) 2025-05-01
CN109476667A (zh) 2019-03-15
TW202202507A (zh) 2022-01-16
SG11201900113UA (en) 2019-02-27
JP6961675B2 (ja) 2021-11-05
TWI745400B (zh) 2021-11-11
KR102537088B1 (ko) 2023-05-25
KR20230074839A (ko) 2023-05-31
MX2021008658A (es) 2021-08-19
AU2021221447B2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
IL259794A (en) Bicyclic inhibitors for pad4
IL259354B (en) inhibitors of cxcr2
IL252756A0 (en) solid forms of ask1 inhibitor
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
ZA201604272B (en) Inhibitors of glutaminase
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL279949A (en) Heterocyclic MCT4 inhibitors
IL257026A (en) Solid state forms of eluxadoline
IL257061A (en) Inhibitors of ezh2
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL265628A (en) Solid state forms of valbenazine
ZA201706282B (en) Solid forms of menaquinols
IL264173A (en) Solid forms of ttk inhibitor
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases